European stock markets were mixed Wednesday's as investors responded to yet another raft earnings reports, company statements and comments from policy makers across the continent.
Hikma Pharmaceuticals fell sharply in London ahead of a crucial decision by the U.S. Food & Drug Administration on whether to approve its generic Advair asthma treatment.
Mylan's setback may not be enough to prevent generic Advair reaching the market in 2017
GlaxoSmithKline beat analysts' expectations for fourth-quarter sales and earnings Wednesday but warned of a significant hit this year from anticipated generic competition to its Advair asthma treatment.
GlaxoSmithKline reports fourth-quarter earnings Wednesday, with investors looking for guidance on the fate of its key Advair drug and the recent pace of organic growth for new products sales.
Spain's Ibex gains more than 1.2%, while Germany's Dax and France's Cac 40 both rose more than 0.6%
European stocks are mixed on Friday, after Beijing sought to calm jittery investors by suspending a circuit breaker system that halted trading twice this week.
